Global Colorectal Cancer Drugs Market 2015-2019

Description: About Colorectal Cancer

Colorectal cancer refers to malignancies that originate in the rectum or the colon. It is also known as bowel cancer. Formation of adenocarcinomas is the most common feature of colorectal cancer. The cancer starts as a polyp in the inner wall of the colon or rectum. These polyps can be benign or malignant. Colorectal cancer is the third most common cancer in the US. Some of the risk factors that can cause colorectal cancer are lifestyle changes, old age, genetic disorders, family history, and inflammatory bowel disease. Some of the symptoms of colorectal cancer are blood in stool, decrease in appetite, constipation, weight loss, nausea, bloating, and pelvic pain. Colorectal cancer can be classified into four broad stages. Colorectal cancer can be treated using surgical, chemotherapeutic, biologic, and radiation therapies.

The analysts forecast the global colorectal cancer drugs market to grow at a CAGR of 3.62% over the period 2014-2019.

Covered in this Report
This report covers the present scenario and the growth prospects of the global colorectal cancer drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of colorectal cancer.

Based on the type of molecule, the market is grouped into two categories:
- Biologics
- Small molecules

Based on the route of administration, the market is grouped into two categories:
- Oral
- Parenteral

This report covers the present scenario and the growth prospects of the global colorectal cancer drugs market for the period 2015-2019 in the following regions:
- Americas: The principal countries focused upon in this region are the US, Canada, Mexico, and Brazil
- EMEA: The principal countries focused upon in this region are the UK, Germany, Italy, France, Spain, Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and UAE. Germany, Italy, and the UK are the leading European countries in terms of elderly population
- APAC: The principal countries focused upon in this region are Japan, China, Australia, Singapore, South Korea, and India.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors as well as the competitive performances of their product portfolios in the market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by vendors and the market at large, as well as the key trends that are emerging in the market.

The report, Global Colorectal Cancer Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC; it also covers the global colorectal cancer drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions
- Americas
- APAC
- EMEA

Key Vendors
- Amgen
- Bayer
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
Other Prominent Vendors
- Accord Healthcare
- Advenchen Laboratories
- Aeterna Zentaris
- AstraZeneca
- Bayer Healthcare
- Boehringer Ingelheim
- Daiichi Sankyo
- Debiopharm
- Eisai
- Eli Lilly
- Immodulon Therapeutics
- Mologen
- Mylan
- Nektar Therapeutics
- Oncothyreon
- Otsuka Pharmaceutical
- Precision Biologics
- Sun Pharmaceutical
- Symphogen
- Taiho
- Takeda
- Teva
- ThromboGenics
- Xbiotech
- Yakult Honsha

Market Drivers
- Increase in population of patients
- For a full, detailed list, view our report

Market Challenges
- Loss of patent exclusivity
- For a full, detailed list, view our report

Market Trends
- Dominance of biologics
- For a full, detailed list, view our report

Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Exhibit 14: Segmentation of Global Colorectal Cancer Drugs Market by Type of Molecules, 2014
Exhibit 15: Segmentation of Global Colorectal Cancer Drugs Market by Route of Administration
Exhibit 16: Segmentation of Global Colorectal Cancer Drugs Market by Route of Administration, 2014
Exhibit 17: Global Colorectal Cancer Drugs Market by Geographical Segmentation 2014
Exhibit 18: Colorectal Cancer Drugs Market in Americas 2014-2019 ($ millions)
Exhibit 19: Colorectal Cancer Drugs Market in EMEA 2014-2019 ($ millions)
Exhibit 20: Colorectal Cancer Drugs Market in APAC 2014-2019 ($ millions)
Exhibit 21: Drivers of the Global Colorectal Cancer Drugs Market
Exhibit 22: Challenges of the Global Colorectal Cancer Drugs Market
Exhibit 23: Trends of the Global Colorectal Cancer Drugs Market
Exhibit 24: YoY Growth Rate of the Major Colorectal Cancer Drugs 2010-2014 ($ millions)
Exhibit 25: F. Hoffmann-La Roche: Product Portfolio
Exhibit 26: Avastin: Global Revenue and YoY Growth Rate 2010-2014 ($ millions)
Exhibit 27: Avastin: Region-wise Revenues 2010-2014 ($ millions)
Exhibit 28: Avastin: YoY Revenues and Growth Rate of Avastin in the US 2010-2014 ($ millions)
Exhibit 29: Avastin: YoY Revenues and Growth Rate of Avastin in Europe 2010-2014 ($ millions)
Exhibit 30: Avastin: YoY Revenues and Growth Rate of Avastin in Japan 2010-2014 ($ millions)
Exhibit 31: YoY International Revenues and Growth Rate of Avastin 2010-2014 (Except US, Europe, Japan) ($ millions)
Exhibit 32: Xeloda: Global Revenue and YoY Growth Rate 2010-2014 ($ millions)
Exhibit 33: Xeloda: Region-wise Revenues 2010-2014 ($ millions)
Exhibit 34: Xeloda: YoY Revenues and Growth Rate of Xeloda in the US ($ millions)
Exhibit 35: Xeloda: YoY Revenues and Growth Rate of Xeloda in Europe ($ millions)
Exhibit 36: Xeloda: YoY Revenues and Growth Rate of Xeloda in Japan ($ millions)
Exhibit 37: Xeloda: YoY International Revenues and Growth Rate of Xeloda (Except US, Europe, Japan) ($ millions)
Exhibit 38: Merck Serono: Product Portfolio
Exhibit 39: Erbitux: Revenue and YoY Growth Rate except US and Canada 2010-2014 ($ millions)
Exhibit 40: Erbitux: Region-wise Revenues 2012-2014 ($ millions)
Exhibit 41: Erbitux: Revenue and YoY Growth Rate in Europe 2012-2014 ($ millions)
Exhibit 42: Erbitux: Revenue and YoY Growth Rate in Emerging Markets 2012-2014 ($ millions)
Exhibit 43: Erbitux: Revenue and YoY Growth Rate in ROW 2012-2014 ($ millions)
Exhibit 44: Amgen: Product Portfolio
Exhibit 45: Eloxatin: Global Revenue and YoY Growth Rate 2010-2014 ($ millions)
Exhibit 46: Eloxatin: Region-wise Revenues 2010-2014 ($ millions)
Exhibit 47: Eloxatin: YoY Revenues and Growth Rate of Eloxatin in the US ($ millions)
Exhibit 48: Eloxatin: YoY Revenues and Growth Rate of Eloxatin in Europe ($ millions)
Exhibit 49: Eloxatin: YoY Revenues and Growth Rate of Eloxatin in Emerging Markets ($ millions)
Exhibit 50: Eloxatin: YoY Revenues and Growth Rate of Eloxatin in ROW 2010-2014 ($ millions)
Exhibit 51: Zaltrap: Global Revenue and YoY Growth Rate 2012-2014 ($ millions)
Exhibit 52: Zaltrap: Region-wise Revenue 2012-2014 ($ millions)
Exhibit 53: Sanofi: Product Portfolio
Exhibit 54: Sanofi: YoY Revenues and Growth Rate of Sanofi in the US ($ millions)
Exhibit 55: Sanofi: YoY Revenues and Growth Rate of Sanofi in Europe ($ millions)
Exhibit 56: Sanofi: YoY Revenues and Growth Rate of Sanofi in Emerging Markets ($ millions)
Exhibit 57: Sanofi: YoY Revenues and Growth Rate of Sanofi in ROW 2010-2014 ($ millions)
Exhibit 58: Bayer: Product Portfolio
Exhibit 59: Bayer: Business segmentation by revenue 2014
Exhibit 60: Bayer: Business segmentation by revenue 2013-2014 ($ millions)
Exhibit 61: Bayer: Geographical segmentation by revenue 2013-2014 ($ millions)
Exhibit 62: Amgen: Business segmentation by revenue 2013
Exhibit 63: Amgen: Product Portfolio by revenue 2013
Exhibit 64: Amgen: Business segmentation by revenue 2012 and 2013 (US$ billion)
Exhibit 65: Amgen: Geographical Segmentation by revenue 2013
Exhibit 66: Amgen: Business segmentation by revenue 2014
Exhibit 67: Merck Serono: Geographical Segmentation by revenue 2013
Exhibit 68: Merck Serono: Key Product Offerings (Based on Therapeutic Areas)
Exhibit 69: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
Exhibit 70: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 71: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
Exhibit 72: Bristol-Myers Squibb Co.: Sales by Geography 2013 (Diagnostics Division)
Exhibit 78: Sanofi SA: Business Segmentation
Exhibit 79: Sanofi SA: Revenue by Business Segmentation 2013
Exhibit 80: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 81: Sanofi SA: Sales Revenue by Geographical Segmentation 2013

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/3287784/](http://www.researchandmarkets.com/reports/3287784/)
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Global Colorectal Cancer Drugs Market 2015-2019
Web Address: http://www.researchandmarkets.com/reports/3287784/
Office Code: SCH3QVIA

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td></td>
</tr>
<tr>
<td>Single User:</td>
<td>USD 3000</td>
</tr>
<tr>
<td>1 - 5 Users:</td>
<td>USD 3500</td>
</tr>
<tr>
<td>Site License:</td>
<td>USD 4500</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td>USD 10000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]
First Name: __________________________ Last Name: __________________________
Email Address: * __________________________
Job Title: __________________________
Organisation: __________________________
Address: __________________________
City: __________________________
Postal / Zip Code: __________________________
Country: __________________________
Phone Number: __________________________
Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:
Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp